Role of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy

Egyptian Journal of Radiology and Nuclear Medicine

Table 3 Presence of pathology with different variables

		Negative pathology (no. = 22)	Positive pathology (no. = 28)	Test value	p value	Sig.
Age (years)	Mean ± SD	43.23 ± 6.20	46.21 ± 5.21	− 1.851•	0.070	NS
Age (years)	Range	32–55	37–55	− 1.851•	0.070	NS
Hormonal therapy duration (year)	Mean ± SD	1.86 ± 1.18	2.79 ± 1.48	− 2.435	0.019	S
Hormonal therapy duration (year)	Range	0.33–5	0.75–5	− 2.435	0.019	S
Atypicalvaginal bleeding	No	22 (100.0%)	19 (67.9%)	8.624*	0.003	HS
Atypicalvaginal bleeding	Yes	0 (0.0%)	9 (32.1%)	8.624*	0.003	HS
US-endo. thickness (mm)	Mean ± SD	6.45 ± 1.52	13.19 ± 6.14	− 5.023	0.000	HS
US-endo. thickness (mm)	Range	3–8	3–30	− 5.023	0.000	HS
US-endo. regular	No	0 (0.0%)	10 (35.7%)	9.821*	0.002	HS
US-endo. regular	Yes	22 (100.0%)	18 (64.3%)	9.821*	0.002	HS

p value > 0.05: non-significant (NS), p value < 0.05: significant (S), p value< 0.01: highly significant (HS)
*Chi-square test
•Independent t test